Delay in decision on modifying funded access to mifepristone and misoprostol proposal
PHARMAC would like to advise all interested parties that there will be a delay in the decision on a proposal to list mifepristone in Section B of the Pharmaceutical Schedule from 1 July 2020 and amend the listing of misoprostol in Section B of the Pharmaceutical Schedule enabling it to be supplied on a Practitioners’ Supply Order (PSO) from 1 July 2020.
Consultation on this proposal has now closed. We have determined that we require additional time before a decision can be made on the proposal. This delay will mean that a decision will not be made in time for 1 July 2020 funding changes. We expect a decision to be made, and subsequently notified, on this proposal within the next month.